Literature DB >> 11190285

[Hypertension: microvascular complications].

J S Silvestre1, B I Lévy.   

Abstract

The arterioles, vessels situated before the capillary bed, are responsible for the increased systemic resistances characteristic of hypertension. In short, three abnormalities are observed in the arterioles of hypertensives: abnormally high vasoconstrictor tone, essentially due to sympathetic hyperactivity, hypertrophic remodelling or increased wall thickness/radius ratio of the arteriole promoting both the increase in vasoconstriction tone and reduction of the vascular lumen, rarefaction of the microvascular bed which contributes to the increase in the haemodynamic resistances. These three factors are observed to different degrees in all forms of hypertension; their influence varies with the organ involved and the stage of the disease. A change in therapeutic strategy has occurred over the last 20 years in the field of hypertension. Before the 1980's, anti-hypertensive therapy was essentially aimed at a vasomotor target: the drugs used had a vasodilatory effect on the resistive arterioles or decreased their response to vasoconstrictor agents. From the mid-1980's, a lot of research was made into the therapeutic possibilities of limiting or correcting the hypertrophic remodelling of the arteries and arterioles of hypertensive patients. In the last few years, the vascular rarefaction in hypertension has been considered to be a significant factor and the possibility of correcting the structural abnormality has become a new therapeutic option.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11190285

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  1 in total

1.  Exercise Training Attenuates Sympathetic Activity and Improves Morphometry of Splenic Arterioles in Spontaneously Hipertensive Rats.

Authors:  Marina de Paiva Lemos; Gustavo Ribeiro da Mota; Moacir Marocolo; Carla Cristina de Sordi; Rosângela Soares Chriguer; Octávio Barbosa Neto
Journal:  Arq Bras Cardiol       Date:  2018-03       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.